Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/564934 http://scihub22266oqcxt.onion/10.1155/2015/564934 C4442310!4442310 !26078757     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26078757 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Int+J+Endocrinol 2015 ; 2015 (ä): 564934 Nephropedia Template TP {{tp|p=26078757 |t=2015. Osteoprotegerin in Cardiometabolic Disorders |pdf=|usr=}}{{26078757 }} gab.com Text Osteoprotegerin in Cardiometabolic Disorders JO: Int J Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=26078757 #FOAvip Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD. This review focuses on the relationship between circulating OPG and different endocrine cardiometabolic alterations such as type 1 and 2 diabetes. The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out. Moreover, OPG modulation by different treatments is also established. Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered. Twit Text FOAVip Osteoprotegerin in Cardiometabolic Disorders ????Int J Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=26078757 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26078757 #FOAvip English Wikipedia <ref>{{Cite pmid|26078757 }}</ref> Osteoprotegerin in Cardiometabolic Disorders #MMPMID26078757 Pérez de Ciriza C ; Lawrie A ; Varo N Int J Endocrinol 2015[]; 2015 (ä): 564934 PMID26078757 show ga Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD. This review focuses on the relationship between circulating OPG and different endocrine cardiometabolic alterations such as type 1 and 2 diabetes. The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out. Moreover, OPG modulation by different treatments is also established. Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered. äOsteoprotegerin in Cardiometabolic Disorders (epmc).pdf DeepDyve Pubget Overpricing